Sector News

Lonza to expand development services for mammalian products in Singapore

October 10, 2021
Life sciences

Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced it will invest to expand mammalian development services in Singapore. The expansion will establish additional capacity for cell culture, purification, and analytical services for mammalian biologics.

The increased service capabilities complement the existing offering, consisting of cell line construction services, process development and process characterization services at the mammalian and cell therapy manufacturing site in Singapore.

This investment will expand the current laboratory capabilities by establishing a new 1,800m2 laboratory at Singapore Science Park, increasing the headcount of the mammalian development services team in Singapore to 125 employees. The new laboratory began operations in September. As part of the investment, the existing laboratories at Lonza’s Tuas, Singapore site will be upgraded by the end of 2021.

Jeetendra Vaghjiani, Senior Director of Clinical Development for Mammalian Biologics, Lonza, commented: “The growth of our global manufacturing network brought a need to increase services supporting these assets. The investment to expand our mammalian manufacturing services in Singapore will ensure that our team continues to deliver timely support to our customers, in particular for process development and characterization studies necessary for advancing therapies towards regulatory approvals and commercialization.”

As part of the expansion, Lonza will invest in the latest technology for mammalian process and analytical development through the addition of systems for cell line development, the latest in perfusion and process analytical technology for process development, as well as providing the capability to perform extensive characterization of biopharmaceuticals using mass spectrometry for the first time in Singapore. The investment will also provide opportunities to expand the service offering and strengthen the position for the anticipated market growth in complex protein formats.

The addition of new technology, alongside the increase in capacity and headcount of Lonza’s development services team in Singapore, will provide a comprehensive offering for small- and large-scale GMP mammalian manufacturing services and cell therapy capabilities.

By Lonza, Press Release

Source: lonza.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).